ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol
2011

Study on the Effects of Ranibizumab in Glaucoma Surgery

Sample size: 50 publication 10 minutes Evidence: moderate

Author Information

Author(s): Frank Bochmann, Claude Kaufmann, Christoph Becht, Ivo Guber, Michael Kaiser, Lucas M Bachmann, Michael A Thiel

Primary Institution: Department of Ophthalmology, Lucerne Cantonal Hospital, Lucerne, Switzerland

Hypothesis

Can topical ranibizumab improve outcomes in glaucoma filtration surgery?

Conclusion

Topical ranibizumab may help prevent scarring and has fewer side effects compared to traditional treatments.

Supporting Evidence

  • Ranibizumab is an anti-VEGF drug that may reduce scarring after glaucoma surgery.
  • Previous studies have shown that anti-VEGF treatments can improve wound healing.
  • Topical application of ranibizumab is expected to have fewer side effects than systemic treatments.

Takeaway

This study is testing if a special eye drop can help people who have surgery for glaucoma by preventing scarring.

Methodology

The study has two phases: the first assesses safety in 5 patients, and the second compares ranibizumab to placebo in 50 patients.

Potential Biases

Potential bias in patient selection and treatment allocation.

Limitations

The study may not account for all variables affecting surgery outcomes.

Participant Demographics

Patients aged 18 and older with primary open angle glaucoma, excluding those with previous surgeries or certain conditions.

Statistical Information

P-Value

<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2415-11-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication